Literature DB >> 8017191

Risk factors for an inflammatory response after extracapsular cataract extraction and posterior chamber IOL.

L Drolsum1, M Davanger, E Haaskjold.   

Abstract

Risk factors for developing an inflammatory response after extracapsular cataract extraction with implantation of posterior chamber IOL have been studied. Out of 1154 cases included in the study, an inflammatory response was encountered in 63 eyes (5.5%). The inflammatory response was defined as increased cellular flare and/or as a fibrinous reaction during a follow-up of 4 months. Thirteen of the 63 eyes (20.6%) developed cellular precipitates, and posterior synechias were seen in 34 of these eyes (54.0%). Among 10 pre- and 10 peroperative putative risk factors analyzed in a logistic regression model, 5 variables had a statistically significant influence on the probability of developing postoperative inflammation; 1) Uveitis in history (p = 0.0001), 2) Pseudo-exfoliation syndrome (p = 0.0224), 3) Inability to obtain adequate mydriasis at the start of surgery (p < 0.0001), 4) Problems with IOL implantation (p = 0.0111) and 5) Pigment effusion during surgery (p = 0.0258).

Entities:  

Mesh:

Year:  1994        PMID: 8017191     DOI: 10.1111/j.1755-3768.1994.tb02731.x

Source DB:  PubMed          Journal:  Acta Ophthalmol (Copenh)        ISSN: 0001-639X


  10 in total

1.  Comparison of Preoperative Topical Dexamethasone Phosphate Versus Ketorolac Tromethamine in Maintaining Intraoperative Mydriasis During Small Incision Cataract Surgery.

Authors:  Ashok Kumar Sharma; Hans Raj Sharma; Rajni Sharma; Amrita Singh
Journal:  J Clin Diagn Res       Date:  2016-05-01

2.  Pseudoexfoliation syndrome and secondary cataract.

Authors:  M Küchle; A Amberg; P Martus; N X Nguyen; G O Naumann
Journal:  Br J Ophthalmol       Date:  1997-10       Impact factor: 4.638

3.  Blood-aqueous barrier in pseudoexfoliation syndrome: evaluation by immunohistochemical staining of endogenous albumin.

Authors:  M Küchle; S A Vinores; J Mahlow; W R Green
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-01       Impact factor: 3.117

4.  Impact of tamsulosin exposure on late complications following cataract surgery: retrospective cohort study.

Authors:  Julio González-Martín-Moro; Julio José González-López; Fernando Gómez-Sanz; Jesús Zarallo-Gallardo; Rosario Cobo-Soriano
Journal:  Int Ophthalmol       Date:  2013-10-25       Impact factor: 2.031

5.  Comparison of Ketorolac Tromethamine and Prednisolone Acetate in Preventing Surgically Induced Miosis during Cataract Surgery.

Authors:  Yusuf M Suleiman; Najwa F Krdoghli; Aksam J Ahmad
Journal:  Sultan Qaboos Univ Med J       Date:  2010-04-17

6.  Effects of dexamethasone, diclofenac, or placebo on the inflammatory response after cataract surgery.

Authors:  C-G Laurell; C Zetterström
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

Review 7.  The clinical utility of new combination phenylephrine/ketorolac injection in cataract surgery.

Authors:  Lola Elizabeth Lawuyi; Avinash Gurbaxani
Journal:  Clin Ophthalmol       Date:  2015-07-10

8.  Intracameral phenylephrine and ketorolac injection (OMS302) for maintenance of intraoperative pupil diameter and reduction of postoperative pain in intraocular lens replacement with phacoemulsification.

Authors:  Richard L Lindstrom; James C Loden; Thomas R Walters; Steven H Dunn; J Steven Whitaker; Terry Kim; Gregory A Demopulos; Khiun Tjia
Journal:  Clin Ophthalmol       Date:  2014-09-05

Review 9.  Clinical outcomes after injection of a compounded pharmaceutical for prophylaxis after cataract surgery: a large-scale review.

Authors:  Sydney L Tyson; Robert Bailey; Janika S Roman; Tingting Zhan; Lisa A Hark; Julia A Haller
Journal:  Curr Opin Ophthalmol       Date:  2017-01       Impact factor: 3.761

10.  The Clinical Guiding Role of the Distribution of Corneal Nerves in the Selection of Incision for Penetrating Corneal Surgery in Canines.

Authors:  Zichen Liu; Chang Yu; Yiwen Song; Mo Pang; Yipeng Jin
Journal:  Vet Sci       Date:  2021-12-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.